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Although preclinical experiments are ultimately required to evaluate new therapeutic ultrasound exposures and
devices prior to clinical trials, in vitro experiments can play an important role in the developmental process. A
variety of in vitro methods have been developed, where each of these has demonstrated their utility for various test
purposes. These include inert tissue-mimicking phantoms, which can incorporate thermocouples or cells and
ex vivo tissue. Cell-based methods have also been used, both in monolayer and suspension. More biologically
relevant platforms have also shown utility, such as blood clots and collagen gels. Each of these methods possesses
characteristics that are well suited for various well-defined investigative goals. None, however, incorporate all the
properties of real tissues, which include a 3D environment and live cells that may be maintained long-term post-
treatment. This review is intended to provide an overview of the existing application-specific in vitro methods
available to therapeutic ultrasound investigators, highlighting their advantages and limitations. Additional reporting
is presented on the exciting and emerging field of 3D biological scaffolds, employing methods and materials
adapted from tissue engineering. This type of platform holds much promise for achieving more representative
conditions of those found in vivo, especially important for the newest sphere of therapeutic applications, based on
molecular changes that may be generated in response to non-destructive exposures.
Keywords: Therapeutic ultrasound, Ultrasound bioeffects, In vitro methods, Ex vivo tissues, Tissue-mimicking phantoms,
Biological scaffoldsIntroduction
It was more than 60 years ago when therapeutic ultrasound
(TUS) exposures were first shown to be beneficial in med-
ical practice. In a seminal preclinical study, continuous,
low energy, and non-focused exposures were shown to
stimulate the formation of bone callus in a radial fracture
model in rabbits [1]. Since then, interest and development
in the field of TUS has continued to grow, where presently
hundreds of research centers and universities worldwide
are working to develop and improve applications in the
fields of vascular disease, oncology, and physical therapy
[2]. Whereas non-focused, low intensity TUS exposures
are being used in the clinic for healing [3] and to enhance
local transdermal delivery [4], focused ultrasound (FUS) is* Correspondence: frenkel@cua.edu
†Equal contributors
Department of Biomedical Engineering, Catholic University of America, 620
Michigan Ave NE, Washington, DC 20064, USA
© 2013 Alassaf et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbeing employed for thermally ablating uterine fibroids [5]
and a variety of malignant tumors including those in the
prostate [6], breast [7], pancreas [8], and bone [9]. As FUS
becomes more accepted, additional solid tumors (e.g., in
the kidney and liver) will similarly be routinely treated on
an outpatient basis [10].
Although in vivo preclinical studies are ultimately re-
quired to evaluate new TUS devices and procedures prior
to clinical trials, it is always desirable, when possible, to
carry out studies in vitro in order to minimize animal
experimentation, lower costs and variability, and increase
throughput. In this review, a summary of the existing
in vitro methods will be provided, detailing the manner by
which each method is appropriate for a specific investiga-
tional purpose. This will be preceded by a short section
on some conventional ex vivo methods that are commonly
used. Finally, a section will be presented on a new in vitroLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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biological scaffold models of soft tissues.
Ex vivo tissues
Although not considered a true in vitro method, using
ex vivo tissue is similar to other in vitro methods in that
it is used in lieu of carrying out the exposures in vivo. One
of the most common uses of ex vivo tissue is for evaluating
new and experimental FUS devices for thermally ablating
tissue. The literature is replete with such studies, where
the purpose is to visualize lesion formation, temperature
elevations, or both. Ex vivo tissues that have been used for
this purpose include turkey breast [11], canine prostate
[12], bovine muscle [13], and porcine kidney [14]. These
tissue models can be useful for initial tests for creating
lesions in predictable locations. However, because of the
lack of perfusion (and subsequent convective heat loss),
lesion formation will occur at relative lower rates of energy




Perhaps the most widely used in vitro method for testing
FUS exposures are phantoms made from tissue-mimicking
materials (TMMs) such as polyacrylamide hydrogels [11,15].
The phantoms are translucent, allowing thermal lesions to
be visualized optically, in addition to being detectable with
diagnostic ultrasound. Bovine serum albumin (BSA) is
also added to these phantoms as a heat-sensitive protein
and to increase the attenuation coefficient of the TMM.
When heated sufficiently, the BSA denatures, creating
the visible lesion. These phantoms can also be produced
in any shape or size, depending on the container in which
they are made. One disadvantage of these TMMs is that
even when using relatively high concentrations of BSA, the
attenuation coefficient is still well below that of normal
tissue (where the attenuation coefficient is the most
important tissue characteristic for the generation of heat
[16]). Therefore, relatively greater levels of energy will be
required to produce a thermal lesion when compared to a
typical soft tissue [11]. Another disadvantage is that the
formation of the lesions is an irreversible process; hence,
the phantoms cannot be reused. The manner by which
these phantoms can be employed is demonstrated in
Figure 1.
Recently, more advanced TMMs have been developed,
possessing characteristics of soft tissue important for
investigating the thermal effects of FUS exposures.
One such TMM was produced from gellan gum, a high-
temperature hydrogel matrix, which was combined with
various-sized aluminum oxide particles and other constitu-
ents. This TMM was shown to be reusable when generating
temperature elevations sufficient for thermal ablation ofthe tissue [17]. In a follow-up study, thermocouples
were embedded in the TMM, demonstrating its utility
for characterizing temperature elevations generated with
these exposures [18].
Tissue-based methods
A variety of in vitro TUS studies have been carried out
using what can be termed ‘tissue-based’ methods. One of
the most popular are blood clots made from fresh, whole
blood confined in an acoustically compatible material. In
one such study, 1 ml of whole blood was collected from
healthy volunteers and closed off in appropriately sized
sections of pediatric Penrose tubing. Pulsed FUS (pFUS)
exposures followed by immersions in tissue plasminogen
activator (tPA) were subsequently shown to improve
thrombolysis when compared to the tPA on its own [19].
This same in vitro clot model was used in a follow-up
study to help elucidate the manner by which these
enhanced therapeutic results were obtained. Investigations
showed improved bioavailability of the tPA in the clots,
where the methods used included scanning electron
microscopy, fluorescently tagged antibodies specific to the
tPA, and fluorescence recovery after photobleaching [20].
In another in vitro clot study, the tPA was radiolabeled
with 125I. Using a gamma counter on serial sections of the
clots, this study showed how low energy, non-focused ultra-
sound (LEnFUS) exposures could improve the penetration
of the agent into the clots [21].
Other in vitro methods may also be considered tissue-
based even though they do not contain any original com-
ponents of tissue. They are, however, comprised of one
or more purified components found in tissue, where
the structural function of these molecules realistically
represents those found in vivo. One example is the use
of fibrin gels, fibrin being an insoluble protein pro-
duced in response to bleeding. It is a major component
of a blood clot, arranged in long fibrous chains. Its
structural function is to entangle platelets, leading to
the formation of a clot. A number of studies have been
carried out with purified fibrin gels, using LEnFUS. The
exposures were shown to create a number of effects
important for enhancing thrombolysis. These included
structurally induced changes for enhancing flow through
the fibrin [22], as well as other changes for improving
binding of tPA to the fibrin itself, a requirement for
fibrinolysis [23].
Collagen is another naturally occurring polymer in the
body, whose structure can also affect the delivery of
drugs [2]. Fibrillar collagen in the extracellular matrix of
solid tumors, for example, can limit interstitial transport,
preventing sufficient and uniform delivery of anticancer
agents. This is especially true in the case of large agents
such as viral gene delivery vectors whose size can be
greater than the spaces between the fibers [24,25]. Studies
Figure 1 Optical and ultrasound visualization of different types of lesions in 6% BSA polyacrylamide TMM phantoms. The ‘cigar’-shaped
lesions (a) are typically created through thermal mechanisms only. The ‘tadpole’-shaped (b) and ‘egg’-shaped (c) lesions on the other hand are
created by acoustic cavitation activity in the prefocal region (the FUS ultrasound transducer was on the right side). This interpretation is
supported by the fact that the cavitation-based lesions are more visible by ultrasound due to the enhanced echogenicity of these regions
(reprinted with permission from [11]).
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looking at permeability, diffusion, and convection for
tracer molecules [26]. Similar collagen gels (the collagen
being the same type found in the extracellular matrix
of mammalian tissue) were used to investigate the effect
of pFUS exposures on transport. The exposures were
previously shown to generate gaps between parenchymal
cells in animal models of both skeletal muscle [27] and
solid tumors [28]. These structural changes increased
the effective pore size of the tissue, resulting in enhanced
convective mass transport of injected nanoparticles (NPs).
The gels were given similar exposures and then immersed
in the same fluorescently labeled NPs, 100 nm in diameter.
Macroscopic fluorescent imaging showed the particles to
initially be taken up only in the region of the focal zone.
Twenty-four hours later, the NPs were still in the same
region, where they were also shown to diffuse freely in
the same gels without collagen (Figure 2). Similar to the
effects reported previously in solid tumors [28], skeletal
muscle [27], and blood clots [19,20], it is thought that the
repetitive radiation force-induced displacements produced
by the exposures may have created structural alterations;
specifically the disruption of the organizational structure
of the collagen fibers. As in the other studies, these effects
could have potentially enabled improved transport through
the gels (VF, unpublished).
Cultured cells
Studies on the effects of ultrasound are being performed
with cultured cells [29,30], using either adherent cells in
monolayer [31] or cells in suspension [32]. The appeal of
having a controlled and reproducible medium of living
cells is understandably attractive, which can facilitatehigh-throughput experimentation at relatively low cost
when compared to animal studies. These experimental
setups are, however, problematic from a variety of per-
spectives. The cells in suspension are of course not rep-
resentative of in vivo conditions. Ultrasound exposures
can generate streaming in the fluid as a result of the at-
tenuation of energy [33]. This can induce mixing of the
cells, creating conditions that are even further from those
found in vivo. The same goes for a single layer of cells
in culture wells, where the majority in vitro ultrasound
studies are done. Here, the cells are backed on one side by
incompressible plastic and on the other by a comparatively
large volume of unconfined fluid. Furthermore, ultrasound
transmission through culture wells is inefficient, resulting
in mode conversion, heat generation, and the potential
formation of standing waves within the cell volume.
These factors combined can lead to uncertainties of up
to 700% in the actual ultrasound exposure experienced by
the cells [30].
A comparatively large number of in vitro studies have
been carried out investigating sonoporation (i.e., the use
of ultrasound to generate pores to enhance drug and gene
delivery to individual cells [34]). These include studies, for
example, that use ultrasound contrast agents to enhance
acoustic cavitation for this purpose [35]. These studies,
typically carried out in a monolayer of cells, in open cul-
ture wells, typify the lack of suitability of these experimen-
tal setups for representing in vivo conditions. As will be
described later in this review, one of the most important
factors controlling cavitation activity is the geometry in
which the bubble is confined [36]. The different possible
experimental configurations for in vitro studies with
cultured cells appear in Figure 3.
Figure 2 Nanoparticle uptake in type I collagen gels. pFUS exposures in the gels were provided at a single location, after which the gels
were immersed in a suspension of 100-nm diameter, fluorescently labeled, polystyrene NPs. In all three gels (a, b, and c), the NPs were initially
taken up only in the region of treatment. Even at 24 h later, the NPs were somewhat more diffuse but still found to be restricted to the treated
region (VF, unpublished).
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So far, all the in vitro methods that have been discussed
have involved attempts to reproduce, to one degree or
another, the in vivo environment, where one or more
biological components are included. Systems, however,
have also been developed to investigate the effects of only
a single and very specific characteristic, where actual bio-
logical components were not required. One example is the
work of Sassaroli and Hynynen who carried out extensive
investigations into the manner by which the diameter
of a vessel will affect various aspects of acoustic cavitation
activity, including the resonance frequency and the damping
coefficient [36-38]. The importance of these studies was
based on the principle that bubble activity under the
geometrical confines of a blood vessel can be very different
than that in free field (i.e., in an unconfined or infinite
medium). In addition to mathematical modeling and
simulations, the investigators also developed a number of
experimental setups. These involved a FUS transducer di-
rected at micron-sized tubes, at which a passive cavitation
detector was also directed. Among the factors that were
investigated was the relationship between the diameter
of the tube and the acoustic pressure threshold for the
induction of cavitation. Earlier studies used tubes made
from silica and polyester [38]. More recently, they ex-
tended their investigations to using agar gels, in which
tunnels were created to more realistically simulate small
blood vessels in vivo [36]. This experimental setup appears
in Figure 4.
Biological scaffolds
Living tissues are exposed to a multiplicity of internal
and external environments, influencing their growth and
regeneration. One of the major design factors in tissueengineering is creating in vitro environments comparable
to native tissue for growing cells and tissues [39]. The
surroundings of living cells in the body include a three-
dimensional (3D) architecture, where interactions occur
between cells, as well as between individual cells and the
extracellular matrix (ECM). Despite this, the vast majority
of in vitro studies are carried out in 2D cultures for the
sake of simplicity. This type of environment will ultimately
lead to the development of cells that are physiologically
compromised [40]. 3D scaffolds, for example, were found
to be superior to 2D cultures for neural cell differentiation
from embryonic stem cells [41]. For many studies, such
as testing cells for sensitivity to drugs, 2D cultures may
be sufficient [42]. However, it is widely accepted that 3D
scaffolds are essential for realistically evaluating the effects
of mechanical stimuli on cells, especially in terms of both
their morphology and biochemical responses through the
process of mechanotransduction [43]. These mechanical
stimuli can include dynamic compression [44], intermittent
hydrostatic pressure [45], rotating shear stress [46], and
ultrasound [47]. In addition to 3D organization, clinically
relevant cell biology research using in vitro models
requires the multicellular complexity of an organ, as
well as an ECM for the required cell interactivity, while
still allowing a variety of experimental interventions to be
performed [40].
3D biological scaffolds have shown great potential in
applications in regenerative medicine, such as for healing
of bone fractures [48]. In addition to providing physical
support for the cells, these structures may provide a variety
of functions including the modulation of signaling pathways
for growth, proliferation and differentiation of the cells, as
well as for their survival [49]. 3D biological scaffolds may
also serve as a reproducible platform for a host of biological
Figure 3 Experimental setups for ultrasound treatment of cultured cells. (a) The ultrasound transducer (T) is positioned directly below a
culture well containing the cells (S). Acoustic gel is used to couple between the transducer and the well. (b) Degassed water is used to couple
between the transducer and the sample. An ultrasound absorber (UA) is used to prevent the reflection of the ultrasound waves. (c) Similar to
setup B however with a variation in orientation. (d) The ultrasound transducer is inserted into the well. This setup is typically used for small
samples in 24- or 96-well plates (reprinted with permission from [29]).
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out using TUS and 3D biological scaffolds. In one,
chondrocytes were seeded in chitosan scaffolds and ex-
posed to LEnFUS. Compared to controls, the cells in the
treated scaffolds had higher cellular viability and higher
levels of type II collagen in the extracellular matrix [47].
In another study, pulsed LEnFUS was shown to increase
adhesion of osteoblast precursor cells in trabecular calcium
phosphate scaffolds [50]. Pretreating scaffolds to ultrasound
prior to adding cells may also be beneficial. A study in
decellularized patella tendon scaffolds, for example, dem-
onstrated that using pulsed LEnFUS at relatively higher
intensities could produce a more porous matrix without
adversely affecting the biochemical constituents orFigure 4 Experimental setup for investigating cavitation activity in ag
the integration of the different elements that were used. (right) A photogra
cavitation detector. All the components were in an acrylic tank filled with d
tunnels just prior to the exposures (reprinted with permission from [36]).damaging the architecture of the scaffolds. The micro-
scopic alterations were shown to improve penetration and
subsequently, recellularization of primary tenocytes [51].
These studies were performed to help elucidate the under-
lying mechanisms involved when using ultrasound in
physical therapy for regenerative purposes. In each study,
however, both the type of scaffold and the cells were
different, as were the experimental setups and ultrasound
devices. To date, there are no standardized platforms
available to ultrasound investigators that can realistic-
ally reproduce conditions in vivo in a consistent and cost-
effective manner; especially for soft tissue models.
In our laboratory, we are presently developing scaffolds
specifically designed for evaluating the biological effects ofar gel tunnels. (left) A schematic representation of the setup showing
ph of the setup showing the gel, the FUS transducer, and the
egassed water used for coupling. Microbubbles were injected into the







Ex vivo tissue + + −
Tissue-mimicking materials + + −
Tissue-based methods + + −
Cultured cells − − +
Non-biological methods + +/− −
Biological scaffolds + + +
Figure 5 Chitosan-gelatin biological scaffolds. (left) 2D scaffold: (a) brightfield image showing the fibrous structure of the scaffold; (b)
fluorescent image of the same scaffold in (a), where the nuclei of fibroblasts are visible, stained with DAPI. Bar = 100 μm. (right) 3D scaffolds
sectioned, stained with Masson's trichrome (red, scaffold; purple, fibroblasts), and observed with brightfield microscopy. (c) Edge region of a non-
cellularized scaffold (bar = 200 μm). (inset) Entire scaffold (height = 7 mm; radius = 20 mm). (d,e) Regions of cellularized scaffolds (outer surface
at top) (bar = 50 μm). Pore sizes range from 50 to 200 μm, with various degrees of cellularization.
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scaffolds is based on existing ones for bone-mimicking
scaffolds, typically incorporating naturally occurring poly-
mers such as gelatin and collagen [52]. Our scaffolds
possess characteristics of soft tissues, being comprised of
chitosan and gelatin. Whereas chitosan confers beneficial
structural characteristics to the scaffolds [53], gelatin con-
tains favorable cell-binding properties [54]. This formula-
tion, for example, is being used to develop implantable
dermal constructs to which an epidermal layer would then
be adhered [55]. One of the attractive features of the 3D
scaffolds is that they can be formed into any shape or size,
determined by the container (i.e., mold) in which they are
produced. A deeper and narrower design, for example,
could be more suitable for a focused beam. A broader and
shallower scaffold on the other hand could be used for
exposures provided with planar, non-focused transducers.
One of the exciting possibilities that we have begun
investigating is the use of 2D scaffolds ‘rolled up’ in to
pseudo-blood vessels that would then be embedded in
an inert gel phantom, which would provide structural
support for the vessel. A blood-mimicking fluid [56]
could then be circulated through the vessel while ultra-
sound exposures are being carried out. Such a setup would
allow investigations of ultrasound-mediated drug delivery
applications. This includes sonoporation [57], and also the
deployment of drugs from temperature sensitive liposomes
[58]. Examples of both 2D and 3D biological scaffolds that
we have been preparing appear in Figure 5.In addition to those already discussed, there are other
advantages of the proposed 3D scaffolds over the other
in vitro platforms described so far in regard to the inves-
tigational methodologies that they could potentially facili-
tate. One is that essentially, any cell type could be used.
This includes cells that are stably transfected with reporter
genes whose signals, fluorescent (e.g., green fluorescent
protein) or bioluminescent (e.g., firefly luciferase), could be
imaged in situ. Using promoters for specific genes to be
investigated, such as the gene for heat shock proteins that
respond to the generation of heat [59], repeated imaging
session could be carried out for temporal characterization
of expression over a protracted period post-treatment.
Other methodologies that could be employed, and which
would not be possible in vivo, include in situ fixation [60],
for ‘capturing’ discreet and transient structural alterations
occurring during the exposures, and in situ hybridization
[61], for looking at spatial patterns of gene expression
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structural alterations with induced patterns of gene ex-
pression would enable investigations into phenomena
such as mechanotransduction, the mechanism by which
mechanical signals are converted by cells into biochemical
responses [62].
Conclusions
With the advancement of TUS has come a large and
impressive variety of in vitro methods and platforms
for evaluating these exposures and the devices being
developed to apply them (Table 1). Some have been simple
and straightforward, such as encasing whole blood to rep-
resent an acute blood clot. Others have been more sophis-
ticated, as for tissue-mimicking phantoms fabricated from
a combination of materials through a complex process,
which can also incorporate thermocouples for characteriz-
ing induced temperature elevations. Each one of these
methods has been innovative and effectively served the
specific purpose of the tests being carried out. They also
have contributed to reducing the requirement on animal
testing, in addition to reducing variability and costs, and
expediting the evaluation process.
Today, biological scaffolds are being developed to
evaluate TUS exposures, incorporating live cells in a 3D
environment. These will be used specifically for evaluating
the molecular effects that the exposures can generate and
contribute to the investigative process for determining the
potential of applications based on these effects. As new
applications of TUS continue to be proposed and devel-
oped, one would expect that novel in vitro test methods
and platforms will also arise, offering investigators an even
richer and diverse range of options to facilitate the process,
as well as reduce the demand on animal testing.
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